A Dual Enzyme Inhibitor Boosted Both Endocannabinoids and Had Stronger Behavioral Effects in Rats
The dual FAAH/MAGL inhibitor JZL195 elevated both anandamide and 2-AG in rat brains and produced stronger motor-suppressing effects than the MAGL-only inhibitor JZL184.
Quick Facts
What This Study Found
JZL184, a selective MAGL inhibitor, was able to elevate brain 2-AG levels in rats, contrary to some previous reports suggesting it was ineffective in this species. However, the motor suppression caused by JZL184 was found to operate through a CB1-independent mechanism.
The dual FAAH/MAGL inhibitor JZL195 produced enhanced effects compared to JZL184 alone, simultaneously elevating both anandamide (via FAAH inhibition) and 2-AG (via MAGL inhibition) in the brain. Its behavioral effects, including motor suppression, were more robust than JZL184.
The finding that JZL184's behavioral effects in rats were CB1-independent is notable, as its effects in mice are CB1-dependent, highlighting important species differences in endocannabinoid pharmacology.
Key Numbers
JZL184 elevated 2-AG in rat brain but its motor effects were CB1-independent. JZL195 elevated both anandamide and 2-AG and produced enhanced behavioral effects. Species differences noted between rat and mouse responses.
How They Did This
Researchers compared the neurochemical and behavioral effects of JZL184 (MAGL inhibitor) and JZL195 (dual FAAH/MAGL inhibitor) in rats. Brain endocannabinoid levels were measured after systemic drug administration. Behavioral assessments focused on motor activity. CB1 receptor involvement was tested using antagonist pre-treatment.
Why This Research Matters
Understanding species differences in endocannabinoid pharmacology is critical for translating preclinical findings to humans. The rat is generally considered more predictive of human drug responses than the mouse, so clarifying how endocannabinoid-targeting drugs work in rats is essential for drug development.
The Bigger Picture
Endocannabinoid-modulating drugs are being developed as potential treatments for pain, anxiety, and other conditions. This study clarifies the pharmacology of key research tools in rats, an important preclinical species, and demonstrates that dual inhibition of both major endocannabinoid-degrading enzymes produces stronger effects than targeting either alone.
What This Study Doesn't Tell Us
This was an animal study with limited behavioral measures (primarily motor activity). The CB1-independent mechanism of JZL184 in rats was not fully characterized. The doses used may not be directly relevant to human pharmacology. The study focused on acute administration and did not assess chronic effects.
Questions This Raises
- ?What is the CB1-independent mechanism by which JZL184 suppresses motor activity in rats?
- ?Would dual enzyme inhibition produce stronger therapeutic effects in humans?
- ?Are there safety concerns with simultaneously elevating both endocannabinoids?
Trust & Context
- Key Stat:
- JZL184 elevated 2-AG in rats but its motor effects were CB1-independent, unlike in mice
- Evidence Grade:
- This is a preclinical pharmacology study in rats. It provides important methodological clarifications for the field.
- Study Age:
- Published in 2014. Endocannabinoid enzyme inhibitor pharmacology continues to be refined.
- Original Title:
- The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.
- Published In:
- Pharmacology, biochemistry, and behavior, 124, 153-9 (2014)
- Authors:
- Seillier, Alexandre(4), Dominguez Aguilar, David, Giuffrida, Andrea(6)
- Database ID:
- RTHC-00862
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do species differences matter?
Drugs often work differently in mice and rats, and differently again in humans. Since rats are generally more pharmacologically similar to humans than mice, understanding how endocannabinoid drugs work in rats is a critical step toward clinical development.
What is the advantage of dual enzyme inhibition?
By blocking both FAAH and MAGL simultaneously, dual inhibitors elevate both major endocannabinoids (anandamide and 2-AG) at once. This may produce more robust effects than targeting either system alone.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00862APA
Seillier, Alexandre; Dominguez Aguilar, David; Giuffrida, Andrea. (2014). The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.. Pharmacology, biochemistry, and behavior, 124, 153-9. https://doi.org/10.1016/j.pbb.2014.05.022
MLA
Seillier, Alexandre, et al. "The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.." Pharmacology, 2014. https://doi.org/10.1016/j.pbb.2014.05.022
RethinkTHC
RethinkTHC Research Database. "The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on ..." RTHC-00862. Retrieved from https://rethinkthc.com/research/seillier-2014-the-dual-faahmagl-inhibitor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.